Literature DB >> 17148964

Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure.

Rafael Correa1, Alexandre Harari, Florence Vallelian, Salvador Resino, M Angeles Munoz-Fernandez, Giuseppe Pantaleo.   

Abstract

BACKGROUND: Virus-specific CD4 T cells play a critical role in antiviral immunity. HIV-1-specific CD4 T cells in chronically infected adults are mostly composed of IFN-gamma-secreting cells, whereas a selective defect in IL-2-secreting CD4 T cells has been demonstrated. HIV-1-specific IL-2-secreting CD4 T cells are key components of effective immunity.
OBJECTIVE: To determine the function of HIV-1-specific CD4 T cells in HIV-1 vertically infected children after antiretroviral treatment (ART).
DESIGN: Twenty-three vertically HIV-infected children treated with ART for an extended period (mean 7 years) were retrospectively studied.
METHODS: The function of HIV-1-specific CD4 T cells was determined by their ability to secrete IL-2 and IFN-gamma after stimulation with HIV-1 p55 gag protein using polychromatic flow cytometry.
RESULTS: : Substantial differences in the patterns of CD4 T-cell responses were associated with different conditions of response to ART. Interestingly, children with suppression of viraemia below 50 HIV-1-RNA copies/ml of plasma for at least 2 years showed dominant IL-2 CD4 T-cell responses; children with viraemia below 50 copies but experiencing transient blips of viraemia showed polyfunctional (IL-2 plus IFN-gamma) CD4 T-cell responses; children with uncontrolled high viraemia levels had dominant IFN-gamma CD4 T-cell responses. Furthermore, the total frequency of HIV-1-specific CD4 T cells including IL-2 and IFN-gamma-secreting cells was significantly higher compared with HIV-infected adults with chronic infection.
CONCLUSION: The higher frequency of HIV-1-specific CD4 T cells in children compared with adults and the recovery of IL-2-secreting CD4 T cells after successful ART-mediated suppression of virus replication indicate a greater capacity of immune restoration in children than adults.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17148964     DOI: 10.1097/QAD.0b013e32801120bc

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  Cellular immune responses in human immunodeficiency virus (HIV)-1-infected children: is immune restoration by highly active anti-retroviral therapy comparable to non-progression?

Authors:  M Hainaut; V Verscheure; M Ducarme; L Schandené; J Levy; F Mascart
Journal:  Clin Exp Immunol       Date:  2011-04-19       Impact factor: 4.330

2.  Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study.

Authors:  Simon J Potter; Christine Lacabaratz; Olivier Lambotte; Santiago Perez-Patrigeon; Benoît Vingert; Martine Sinet; Jean-Hervé Colle; Alejandra Urrutia; Daniel Scott-Algara; Faroudy Boufassa; Jean-François Delfraissy; Jacques Thèze; Alain Venet; Lisa A Chakrabarti
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

3.  Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells.

Authors:  Marybeth Daucher; David A Price; Jason M Brenchley; Laurie Lamoreaux; Julia A Metcalf; Catherine Rehm; Elizabeth Nies-Kraske; Elizabeth Urban; Christian Yoder; Diane Rock; Julie Gumkowski; Michael R Betts; Mark R Dybul; Daniel C Douek
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

4.  Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells.

Authors:  Sunil Kannanganat; Chris Ibegbu; Lakshmi Chennareddi; Harriet L Robinson; Rama Rao Amara
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

5.  CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.

Authors:  Jennifer Serwanga; Susan Mugaba; Auma Betty; Edward Pimego; Sarah Walker; Paula Munderi; Charles Gilks; Frances Gotch; Heiner Grosskurth; Pontiano Kaleebu
Journal:  AIDS Res Treat       Date:  2011-01-18

6.  Preservation of lymphocyte functional fitness in perinatally-infected and treated HIV+ pediatric patients displaying sub-optimal viral control.

Authors:  Aaruni Khanolkar; William J Muller; Bridget M Simpson; Jillian Cerullo; Ruth Williams; Sun Bae Sowers; Kiana Matthews; Sara Mercader; Carole J Hickman; Richard T D'Aquila; Guorong Liu
Journal:  Commun Med (Lond)       Date:  2022-03-04

7.  Specific in vitro interferon-gamma and IL-2 production as biomarkers during treatment of chronic Q fever.

Authors:  Teske Schoffelen; Marjolijn C Wegdam-Blans; Anne Ammerdorffer; Marjolijn J H Pronk; Yvonne E P Soethoudt; Mihai G Netea; Jos W M van der Meer; Chantal P Bleeker-Rovers; Marcel van Deuren
Journal:  Front Microbiol       Date:  2015-02-12       Impact factor: 5.640

8.  Recovery of effective HIV-specific CD4+ T-cell activity following antiretroviral therapy in paediatric infection requires sustained suppression of viraemia.

Authors:  Emily Adland; Luisa Mori; Leana Laker; Anna Csala; Maximilian Muenchhoff; Alice Swordy; Masa Mori; Philippa Matthews; Gareth Tudor-Williams; Pieter Jooste; Philip Goulder
Journal:  AIDS       Date:  2018-07-17       Impact factor: 4.177

9.  Human immunodeficiency virus-specific CD8+ T-cell activity is detectable from birth in the majority of in utero-infected infants.

Authors:  Christina F Thobakgale; Dhanwanthie Ramduth; Sharon Reddy; Nompumelelo Mkhwanazi; Chantal de Pierres; Eshia Moodley; Wendy Mphatswe; Natasha Blanckenberg; Ayanda Cengimbo; Andrew Prendergast; Gareth Tudor-Williams; Krista Dong; Prakash Jeena; Gupreet Kindra; Raziya Bobat; Hoosen Coovadia; Photini Kiepiela; Bruce D Walker; Philip J R Goulder
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.